Finally, data on the effects of NET treatment on sexual function are very limited; however, neuroendocrine tumours can express oestrogen receptors/progesterone receptors (ER/PR) or testosterone receptors (TR); thus, checking tumour tissue for ER/PR/TR status prior to considering hormonal therapy for sexual dysfunction should be considered but warrants additional studies. This evidence concerns the gene PGR and neoplasm.